Skip to Main Content

Paper Details

Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.
Cancer Immunol Immunother
15
2021
Author NameAffiliation
Elliot NaidusUniversity of California San Francisco
Elliot NaidusMills-Peninsula Medical Center
Lawrence FongUniversity of California San Francisco
Lawrence FongHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
  • 1 - 4

Datasets

Release 1.2